Leerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat October 21, 2015 1:36 PM Pre-Open Stock Movers 10/21: (KLAC) (ISRG) (SNDK) Higher; (SNTA) (VMW) (TWTR) Lower (more...)October 21, 2015 9:27 AM RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 ResultsOctober 21, 2015 9:22 AM Biogen to cut 11 percent of staff, cancel some drug programs; stock jumpsOctober 21, 2015 7:45 AM Biogen (BIIB) will resume trading at 8:00am ETOctober 21, 2015 7:40 AM Biogen's (BIIB) Phase 3 ASCEND Trial Missed Primary, Secondary EndpointsOctober 21, 2015 7:32 AM Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS OutlookOctober 21, 2015 7:31 AM Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MSOctober 21, 2015 7:31 AM Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year GuidanceOctober 21, 2015 7:30 AM Biogen (BIIB) Halted, News PendingOctober 21, 2015 7:25 AM Trading Radar for 10/21: Coca Cola (KO), GM (GM), AmEx (AXP), Boeing (BA), Kimberly-Clark (KMB) ReportOctober 20, 2015 2:40 PM Biogen (BIIB) Bullish View Reiterated at Jefferies Following Sensitivity AnalysisOctober 20, 2015 7:12 AM